<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Rheum Dis</journal-id><journal-id journal-id-type="iso-abbrev">Ann. Rheum. Dis</journal-id><journal-id journal-id-type="hwp">annrheumdis</journal-id><journal-id journal-id-type="publisher-id">ard</journal-id><journal-title-group><journal-title>Annals of the Rheumatic Diseases</journal-title></journal-title-group><issn pub-type="ppub">0003-4967</issn><issn pub-type="epub">1468-2060</issn><publisher><publisher-name>BMJ Publishing Group</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">24737786</article-id><article-id pub-id-type="pmc">4431324</article-id><article-id pub-id-type="publisher-id">annrheumdis-2013-205060</article-id><article-id pub-id-type="doi">10.1136/annrheumdis-2013-205060</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject></subj-group><subj-group subj-group-type="heading"><subject>Clinical and Epidemiological Research</subject></subj-group><series-title>Extended report</series-title></article-categories><title-group><article-title>Cost-effectiveness of infliximab versus conventional combination treatment in methotrexate-refractory early rheumatoid arthritis: 2-year results of the register-enriched randomised controlled SWEFOT trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Eriksson</surname><given-names>Jonas K</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Karlsson</surname><given-names>Johan A</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Bratt</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Petersson</surname><given-names>Ingemar F</given-names></name><xref ref-type="aff" rid="af2">2</xref><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>van Vollenhoven</surname><given-names>Ronald F</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Ernestam</surname><given-names>Sofia</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Geborek</surname><given-names>Pierre</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Neovius</surname><given-names>Martin</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib></contrib-group><aff id="af1"><label>1</label><addr-line>Clinical Epidemiology Unit, Department of Medicine</addr-line>, <institution>Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af2"><label>2</label><addr-line>Section of Rheumatology, Department of Clinical Sciences Lund</addr-line>, <institution>Lund University</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country></aff><aff id="af3"><label>3</label><addr-line>Rheumatology Unit, Department of Medicine</addr-line>, <institution>Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af4"><label>4</label><addr-line>Section of Orthopedics, Department of Clinical Sciences Lund</addr-line>, <institution>Lund University</institution>, <addr-line>Lund</addr-line>, <country>Sweden</country></aff><aff id="af5"><label>5</label><addr-line>Department of Medicine</addr-line>, ClinTRID, <institution>Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><aff id="af6"><label>6</label><addr-line>Department of Learning, Informatics and Medical Education (LIME)</addr-line>, <institution>Karolinska Institutet</institution>, <addr-line>Stockholm</addr-line>, <country>Sweden</country></aff><author-notes><fn><p><bold>Handling editor</bold> Tore K Kvien</p></fn><corresp><label>Correspondence to</label> Dr Jonas Eriksson, Department of Medicine (Solna), Clinical Epidemiology Unit (T2), Karolinska Institutet, Stockholm SE-171 76, Sweden; <email>jonas.eriksson@ki.se</email></corresp><fn><p>JKE, JAK, PG and MN contributed equally.</p></fn><fn><p><bold>Presentation of Results</bold>: Results were presented in abstract form in an oral presentation at the European League Against Rheumatism annual conference in Madrid, 13 June, 2013 (presentation number OP0094; available at <ext-link ext-link-type="uri" xlink:href="http://www.abstracts2view.com/eular/view.php?nu=EULAR13L_OP0094">http://www.abstracts2view.com/eular/view.php?nu=EULAR13L_OP0094</ext-link>).</p></fn></author-notes><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>15</day><month>4</month><year>2014</year></pub-date><volume>74</volume><issue>6</issue><fpage>1094</fpage><lpage>1101</lpage><history><date date-type="received"><day>12</day><month>12</month><year>2013</year></date><date date-type="rev-recd"><day>19</day><month>3</month><year>2014</year></date><date date-type="accepted"><day>23</day><month>3</month><year>2014</year></date></history><permissions><copyright-statement>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:type="simple" xlink:href="annrheumdis-2013-205060.pdf"></self-uri><abstract><sec><title><offsets xml_i="6472" xml_f="6481" txt_i="11" txt_f="20">Objective</offsets></title><p><offsets xml_i="6492" xml_f="6678" txt_i="21" txt_f="207">To estimate the incremental cost-effectiveness of infliximab versus conventional combination treatment over 21 months in patients with methotrexate-refractory early rheumatoid arthritis.</offsets></p></sec><sec><title><offsets xml_i="6700" xml_f="6707" txt_i="209" txt_f="216">Methods</offsets></title><p><offsets xml_i="6718" xml_f="7321" txt_i="217" txt_f="817">In this multicentre, two-arm, parallel, randomised, active-controlled, open-label trial, rheumatoid arthritis patients with &lt;1 year symptom duration were recruited from 15 rheumatology clinics in Sweden between October 2002 and December 2005. After 3–4 months of methotrexate monotherapy, patients not achieving low disease activity were randomised to addition of infliximab or sulfasalazine+hydroxychloroquine (conventional treatment group). Costs of drugs, healthcare use, and productivity losses were retrieved from nationwide registers, while EuroQol 5-Dimensions utility was collected quarterly.</offsets></p></sec><sec><title><offsets xml_i="7343" xml_f="7350" txt_i="819" txt_f="826">Results</offsets></title><p><offsets xml_i="7361" xml_f="8222" txt_i="827" txt_f="1688">Of 487 patients initially enrolled, 128 and 130 were randomised to infliximab and conventional treatment, respectively. The infliximab group accumulated higher drug and healthcare costs (€27 487 vs €10 364; adjusted mean difference €16 956 (95% CI 14 647 to 19 162)), while productivity losses did not differ (€33 804 vs €29 220; €3961 (95% CI −3986 to 11 850)), resulting in higher societal cost compared to the conventional group (€61 291 vs €39 584; €20 916 (95% CI 12 800 to 28 660)). Mean accumulated quality-adjusted life-years (QALYs) did not differ (1.10 vs 1.12; adjusted mean difference favouring infliximab treatment 0.01 (95% CI −0.07 to 0.08)). The incremental cost-effectiveness ratios for the infliximab versus conventional treatment strategy were €2 404 197/QALY from the societal perspective and €1 948 919/QALY from the healthcare perspective.</offsets></p></sec><sec><title><offsets xml_i="8244" xml_f="8255" txt_i="1690" txt_f="1701">Conclusions</offsets></title><p><offsets xml_i="8266" xml_f="8531" txt_i="1702" txt_f="1967">In early, methotrexate-refractory rheumatoid arthritis, a treatment strategy commencing with addition of infliximab, as compared to sulfasalazine+hydroxychloroquine, was not cost-effective over 21 months at willingness to pay levels generally considered acceptable.</offsets></p></sec><sec><title><offsets xml_i="8553" xml_f="8579" txt_i="1969" txt_f="1995">Trial registration number:</offsets></title><p><offsets xml_i="8590" xml_f="8602" txt_i="1996" txt_f="2008">NCT00764725.</offsets></p></sec></abstract><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title><offsets xml_i="8826" xml_f="8838" txt_i="2017" txt_f="2029">Introduction</offsets></title><p><offsets xml_i="8849" xml_f="9555" txt_i="2030" txt_f="2736">Current guidelines recommend methotrexate as the first-line disease-modifying anti-rheumatic drug (DMARD) in early rheumatoid arthritis (RA), though for many patients methotrexate monotherapy insufficiently controls disease activity. The SWEdish FarmacOTherapy (Swefot) trial is unique among available randomised controlled trials in assessing this common situation by randomly allocating early RA patients with inadequate methotrexate response to addition of a biologic or further conventional DMARDs. Another unique feature is that Swefot was a randomised trial conducted within a clinical quality register, and thereafter enriched through linkage with nationwide health registers for outcome assessment.</offsets><xref rid="R1" ref-type="bibr"><offsets xml_i="9586" xml_f="9587" txt_i="2736" txt_f="2737">1</offsets></xref></p><p><offsets xml_i="9601" xml_f="9734" txt_i="2738" txt_f="2871">As previously reported, addition of the tumour necrosis factor (TNF) inhibitor infliximab resulted in better treatment response at 9,</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="9765" xml_f="9766" txt_i="2871" txt_f="2872">2</offsets></xref><offsets xml_i="9773" xml_f="9818" txt_i="2872" txt_f="2917"> but not 15 or 21 months after randomisation,</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="9849" xml_f="9850" txt_i="2917" txt_f="2918">3</offsets></xref><offsets xml_i="9857" xml_f="10081" txt_i="2918" txt_f="3142"> as compared with addition of the conventional DMARDs sulfasalazine and hydroxychloroquine (also referred to as triple therapy). Superior radiographic outcome and adherence to treatment were observed in the infliximab group,</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="10112" xml_f="10113" txt_i="3142" txt_f="3143">3</offsets></xref><offsets xml_i="10120" xml_f="10121" txt_i="3143" txt_f="3144">
</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="10152" xml_f="10153" txt_i="3144" txt_f="3145">4</offsets></xref><offsets xml_i="10160" xml_f="10240" txt_i="3145" txt_f="3225"> while no differences were detected in quality of life or work loss improvement.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="10271" xml_f="10272" txt_i="3225" txt_f="3226">4</offsets></xref><offsets xml_i="10279" xml_f="10280" txt_i="3226" txt_f="3227">
</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="10311" xml_f="10312" txt_i="3227" txt_f="3228">5</offsets></xref></p><p><offsets xml_i="10326" xml_f="10434" txt_i="3229" txt_f="3337">Over the last decade, the increasing treatment costs of RA, incurred by the introduction of biologic DMARDs,</offsets><xref rid="R6" ref-type="bibr"><offsets xml_i="10465" xml_f="10466" txt_i="3337" txt_f="3338">6</offsets></xref><offsets xml_i="10473" xml_f="11070" txt_i="3338" txt_f="3935"> have led to a growing interest in economic evaluations to determine whether the increased drug costs will be offset by reduced healthcare use and productivity losses, as well as result in better quality of life. Cost-utility analyses assess the incremental cost-effectiveness ratio, comparing the incremental cost per quality-adjusted life-year (QALY) of alternative interventions. Studies apply a healthcare or societal perspective, the latter including medical costs and other costs to society, such as lost productivity. Two recent reviews summarise available cost-effectiveness studies in RA,</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="11101" xml_f="11102" txt_i="3935" txt_f="3936">7</offsets></xref><offsets xml_i="11109" xml_f="11110" txt_i="3936" txt_f="3937">
</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="11141" xml_f="11142" txt_i="3937" txt_f="3938">8</offsets></xref><offsets xml_i="11149" xml_f="11312" txt_i="3938" txt_f="4101"> none comparing a biologic versus a conventional treatment strategy in patients with early disease and previous DMARD exposure limited to methotrexate monotherapy.</offsets></p><p><offsets xml_i="11319" xml_f="11609" txt_i="4102" txt_f="4392">Here, we present a cost-effectiveness analysis based on a register-enriched randomised trial, comparing the cost per QALY over 21 months of adding infliximab or sulfasalazine and hydroxychloroquine to methotrexate in early RA patients with insufficient response to methotrexate monotherapy.</offsets></p></sec><sec sec-type="methods" id="s2"><title><offsets xml_i="11658" xml_f="11665" txt_i="4394" txt_f="4401">Methods</offsets></title><p><offsets xml_i="11676" xml_f="11737" txt_i="4402" txt_f="4463">The Swefot trial has been described in more detail elsewhere.</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="11768" xml_f="11769" txt_i="4463" txt_f="4464">2</offsets></xref><offsets xml_i="11776" xml_f="12029" txt_i="4464" txt_f="4714"> Briefly, patients with early RA (age ≥18 year; symptom duration &lt;1 year) were recruited from 15 rheumatology units in Sweden between 2002 and 2005. Key inclusion criteria were fulfilment of the 1987 revised American College of Rheumatology criteria,</offsets><xref rid="R9" ref-type="bibr"><offsets xml_i="12060" xml_f="12061" txt_i="4714" txt_f="4715">9</offsets></xref><offsets xml_i="12068" xml_f="12137" txt_i="4715" txt_f="4781"> a disease-activity score based on 28 joint count (DAS28) of &gt;3.2,</offsets><xref rid="R10" ref-type="bibr"><offsets xml_i="12169" xml_f="12171" txt_i="4781" txt_f="4783">10</offsets></xref><offsets xml_i="12178" xml_f="12336" txt_i="4783" txt_f="4941"> no previous DMARD treatment, and no or stably dosed oral glucocorticoid therapy for at least 4 weeks, using at most 10 mg daily prednisolone (or equivalent).</offsets></p><sec id="s2a"><title><offsets xml_i="12361" xml_f="12371" txt_i="4942" txt_f="4952">Procedures</offsets></title><p><italic><offsets xml_i="12390" xml_f="12403" txt_i="4953" txt_f="4966">Run-in period</offsets></italic><offsets xml_i="12412" xml_f="12562" txt_i="4966" txt_f="5116">: At inclusion, all patients started methotrexate monotherapy, with an initial dose of 10 mg per week increased by 5 mg every 2 weeks to 20 mg weekly.</offsets></p><p><italic><offsets xml_i="12577" xml_f="12590" txt_i="5117" txt_f="5130">Randomisation</offsets></italic><offsets xml_i="12599" xml_f="13072" txt_i="5130" txt_f="5600">: After a 3–4 months methotrexate run-in period, patients with low disease activity (DAS28≤3.2) left the trial, while those with a remaining DAS28&gt;3.2 were randomly assigned to addition of either infliximab (3 mg/kg bodyweight, rounded up to the nearest 100 mg increment, administered intravenously at weeks 0, 2, 6, and every 8 weeks thereafter) or sulfasalazine (1000 mg twice daily; orally) and hydroxychloroquine (400 mg daily; orally; conventional treatment group).</offsets></p><p><offsets xml_i="13079" xml_f="13589" txt_i="5601" txt_f="6111">The centralised randomisation process was carried out using a computer-generated random allocation sequence. The statistician who prepared the list had no further role in the study. When a patient at the 3-month visit was judged to be eligible for randomisation, the investigator contacted the central study coordinator by telephone and requested randomisation. We did not use stratification or blocking. Doctors and patients were aware of the treatment allocation (addition of two oral drugs vs one infusion).</offsets></p><p><italic><offsets xml_i="13604" xml_f="13625" txt_i="6112" txt_f="6133">Treatment adjustments</offsets></italic><offsets xml_i="13634" xml_f="13693" txt_i="6133" txt_f="6192">: Allowed treatment changes have been described previously.</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="13724" xml_f="13725" txt_i="6192" txt_f="6193">2</offsets></xref><offsets xml_i="13732" xml_f="14071" txt_i="6193" txt_f="6532"> Most importantly, in case of adverse events, sulfasalazine or hydroxychloroquine could be dose-reduced or withdrawn (while continuing the other). Alternatively, both could be replaced by cyclosporin A (2.5 mg/kg/day; increase up to 5 mg/kg/day allowed), while infliximab could be switched to etanercept (50 mg subcutaneously once weekly).</offsets></p><p><italic><offsets xml_i="14086" xml_f="14095" txt_i="6533" txt_f="6542">Follow-up</offsets></italic><offsets xml_i="14104" xml_f="14457" txt_i="6542" txt_f="6895">: Visits were scheduled at run-in, randomisation, and 3, 6, 9, 15 and 21 months after randomisation. Patients could discontinue the assigned treatment at any time for lack of effectiveness, side-effects, or by own choice. Register-based follow-up continued despite protocol breach, and treatment was thereafter decided by the responsible rheumatologist.</offsets></p></sec><sec id="s2b"><title><offsets xml_i="14488" xml_f="14501" txt_i="6897" txt_f="6910">Study outcome</offsets></title><p><offsets xml_i="14512" xml_f="14632" txt_i="6911" txt_f="7031">The primary outcome of the Swefot trial was achievement of a European League Against Rheumatism good treatment response,</offsets><xref rid="R11" ref-type="bibr"><offsets xml_i="14664" xml_f="14666" txt_i="7031" txt_f="7033">11</offsets></xref><offsets xml_i="14673" xml_f="14706" txt_i="7033" txt_f="7066"> and has been reported elsewhere.</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="14737" xml_f="14738" txt_i="7066" txt_f="7067">2</offsets></xref><offsets xml_i="14745" xml_f="14970" txt_i="7067" txt_f="7292"> The current study analysed cost-effectiveness by calculating the incremental cost-effectiveness ratio (€ per QALY), defined as the between-group difference in accumulated costs divided by the difference in accumulated QALYs.</offsets></p></sec><sec id="s2c"><title><offsets xml_i="15001" xml_f="15023" txt_i="7294" txt_f="7316">Perspectives and costs</offsets></title><p><offsets xml_i="15034" xml_f="15305" txt_i="7317" txt_f="7588">The cost-effectiveness analysis was conducted from a healthcare and societal perspective. Costs included antirheumatic drugs, inpatient care (including surgery), non-primary outpatient care (including day surgery), and work loss due to sick leave, and disability pension,</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="15336" xml_f="15337" txt_i="7588" txt_f="7589">5</offsets></xref><offsets xml_i="15344" xml_f="15564" txt_i="7589" txt_f="7809"> estimated during 21 months of follow-up. Baseline costs, used for adjustment, were defined as accumulated costs during 60 days before randomisation. All costs were converted to 2011 euros (€; exchange rate €1=9.03 SEK).</offsets></p><p><offsets xml_i="15571" xml_f="15728" txt_i="7810" txt_f="7967">Data on inpatient and non-primary outpatient care were retrieved from the National Patient Register kept at the Swedish National Board of Health and Welfare.</offsets><xref rid="R12" ref-type="bibr"><offsets xml_i="15760" xml_f="15762" txt_i="7967" txt_f="7969">12</offsets></xref><offsets xml_i="15769" xml_f="15900" txt_i="7969" txt_f="8100"> Costs were calculated using the diagnostic-related group-coding system, a weighted average of costs per disease group, from 2011 (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.socialstyrelsen.se"><offsets xml_i="15973" xml_f="16002" txt_i="8100" txt_f="8129">http://www.socialstyrelsen.se</offsets></ext-link><offsets xml_i="16013" xml_f="16015" txt_i="8129" txt_f="8131">).</offsets></p><p><offsets xml_i="16022" xml_f="16210" txt_i="8132" txt_f="8320">Antirheumatic drug use (including biologic and conventional DMARDs, glucocorticoids and non-steroidal anti-inflammatory drugs) was collected from the Swedish Rheumatology Quality register,</offsets><xref rid="R13" ref-type="bibr"><offsets xml_i="16242" xml_f="16244" txt_i="8320" txt_f="8322">13</offsets></xref><offsets xml_i="16251" xml_f="16383" txt_i="8322" txt_f="8454"> in which drug doses and frequencies were recorded during the Swefot trial. Costs were calculated using 2011 drug prices in Sweden (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.tlv.se"><offsets xml_i="16444" xml_f="16461" txt_i="8454" txt_f="8471">http://www.tlv.se</offsets></ext-link><offsets xml_i="16472" xml_f="16610" txt_i="8471" txt_f="8609">). For intravenous medications, costs proportional to the administered dose was used, not accounting for possible redundant drug material.</offsets></p><p><offsets xml_i="16617" xml_f="16693" txt_i="8610" txt_f="8686">Day-level data on work loss were retrieved from the Social Insurance Office.</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="16724" xml_f="16725" txt_i="8686" txt_f="8687">5</offsets></xref><offsets xml_i="16732" xml_f="17018" txt_i="8687" txt_f="8973"> In the main analysis, the human capital method was used, including all accumulated days of sick leave and disability pension. The impact of using, instead, the friction-cost method was tested in a sensitivity analysis, with a friction period of 6 months for individuals to be replaced.</offsets><xref rid="R14" ref-type="bibr"><offsets xml_i="17050" xml_f="17052" txt_i="8973" txt_f="8975">14</offsets></xref><offsets xml_i="17059" xml_f="17244" txt_i="8975" txt_f="9160"> Productivity losses were estimated as the accumulated days of sick leave and disability pension multiplied with the mean average salary per day, including social fees, in Sweden 2011 (</offsets><ext-link ext-link-type="uri" xlink:href="http://www.scb.se"><offsets xml_i="17305" xml_f="17322" txt_i="9160" txt_f="9177">http://www.scb.se</offsets></ext-link><offsets xml_i="17333" xml_f="17335" txt_i="9177" txt_f="9179">).</offsets></p></sec><sec id="s2d"><title><offsets xml_i="17366" xml_f="17371" txt_i="9181" txt_f="9186">QALYs</offsets></title><p><offsets xml_i="17382" xml_f="17528" txt_i="9187" txt_f="9333">QALYs are estimated using utility instruments, of which the EuroQol 5-Dimensions (EQ-5D) is commonly applied in cost-effectiveness analyses of RA.</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="17559" xml_f="17560" txt_i="9333" txt_f="9334">8</offsets></xref><offsets xml_i="17567" xml_f="17568" txt_i="9334" txt_f="9335">
</offsets><xref rid="R15" ref-type="bibr"><offsets xml_i="17600" xml_f="17602" txt_i="9335" txt_f="9337">15</offsets></xref><offsets xml_i="17609" xml_f="17831" txt_i="9337" txt_f="9559"> In the Swefot trial, EQ-5D utility was assessed quarterly, enabling calculation of accumulated QALYs (the area under the utility curve plotted against time) during 21 months from randomisation, using the trapezoid method.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="17862" xml_f="17863" txt_i="9559" txt_f="9560">4</offsets></xref><offsets xml_i="17870" xml_f="17953" txt_i="9560" txt_f="9643"> In the main analysis, the UK EQ-5D preference set was used to calculate utilities,</offsets><xref rid="R16" ref-type="bibr"><offsets xml_i="17985" xml_f="17987" txt_i="9643" txt_f="9645">16</offsets></xref><offsets xml_i="17994" xml_f="18052" txt_i="9645" txt_f="9703"> while the US tariff was tested in a sensitivity analysis.</offsets><xref rid="R17" ref-type="bibr"><offsets xml_i="18084" xml_f="18086" txt_i="9703" txt_f="9705">17</offsets></xref></p></sec><sec id="s2e"><title><offsets xml_i="18124" xml_f="18135" txt_i="9707" txt_f="9718">Discounting</offsets></title><p><offsets xml_i="18146" xml_f="18366" txt_i="9719" txt_f="9939">National pricing and reimbursement agencies generally recommend discounting of costs and effects at 3% annually. Due to our short follow-up, with only 9 months considered for discounting, data are presented undiscounted.</offsets></p></sec><sec id="s2f"><title><offsets xml_i="18397" xml_f="18417" txt_i="9941" txt_f="9961">Statistical analysis</offsets></title><p><offsets xml_i="18428" xml_f="18844" txt_i="9962" txt_f="10378">The Swefot trial was designed to detect a 15% difference in treatment response according to the European League Against Rheumatism good criteria with a statistical power of 90% (α=0.05), but closed after enrolment of 487 patients (statistical power 75% (α=0.05)), mainly due to slower recruitment than anticipated. After the run-in phase, 128 patients were randomised to infliximab and 130 to conventional treatment.</offsets></p><p><offsets xml_i="18851" xml_f="19137" txt_i="10379" txt_f="10665">All randomised patients were analysed according to the intention-to-treat principle, including observed costs and effects during the full 21 months follow-up irrespective of protocol breach. Incremental cost-effectiveness ratios were estimated in a seemingly unrelated regression model,</offsets><xref rid="R18" ref-type="bibr"><offsets xml_i="19169" xml_f="19171" txt_i="10665" txt_f="10667">18</offsets></xref><offsets xml_i="19178" xml_f="19695" txt_i="10667" txt_f="11184"> adjusting for age, sex, EQ-5D, DAS28 and health assessment questionnaire (HAQ) scores at randomisation, and accumulated costs during 60 days before randomisation. Missing HAQ scores at randomisation (n=6) were imputed by a linear regression model with age, sex and DAS28. As previously described, missing utility data were imputed using a linear regression model at randomisation (n=34), and at later time points by linear interpolation or, in the absence of future measurements, by last observation carried forward.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="19726" xml_f="19727" txt_i="11184" txt_f="11185">4</offsets></xref><offsets xml_i="19734" xml_f="19812" txt_i="11185" txt_f="11263"> All analyses (main, and sensitivity analyses) were also conducted unadjusted.</offsets></p><p><offsets xml_i="19819" xml_f="19976" txt_i="11264" txt_f="11421">To estimate the uncertainty around the incremental costs, effects, and cost-effectiveness ratios, non-parametric bootstrapping with 1000 iterations was used.</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="20008" xml_f="20010" txt_i="11421" txt_f="11423">19</offsets></xref><offsets xml_i="20017" xml_f="20161" txt_i="11423" txt_f="11567"> Cost and effect differences in the bootstrap samples approached a normal distribution despite skewed cost and effect distributions (see online </offsets><ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-205060/-/DC1"><offsets xml_i="20278" xml_f="20298" txt_i="11567" txt_f="11587">supplementary figure</offsets></ext-link><offsets xml_i="20309" xml_f="20571" txt_i="11587" txt_f="11849"> S1). By applying different ceiling ratios for willingness to pay per QALY to these bootstrap samples, we computed the probability of cost-effectiveness at different willingness-to-pay thresholds, and presented results in cost-effectiveness acceptability curves.</offsets><xref rid="R20" ref-type="bibr"><offsets xml_i="20603" xml_f="20605" txt_i="11849" txt_f="11851">20</offsets></xref></p><p><offsets xml_i="20619" xml_f="20721" txt_i="11852" txt_f="11954">CIs for between-group differences in cost and QALYs were estimated using non-parametric bootstrapping.</offsets><xref rid="R19" ref-type="bibr"><offsets xml_i="20753" xml_f="20755" txt_i="11954" txt_f="11956">19</offsets></xref><offsets xml_i="20762" xml_f="20819" txt_i="11956" txt_f="12013"> Data were analysed using SAS (V.9.2) and STATA (V.11.0).</offsets></p></sec></sec><sec sec-type="results" id="s3"><title><offsets xml_i="20874" xml_f="20881" txt_i="12016" txt_f="12023">Results</offsets></title><sec id="s3a"><title><offsets xml_i="20910" xml_f="20933" txt_i="12024" txt_f="12047">Patient characteristics</offsets></title><p><offsets xml_i="20944" xml_f="21071" txt_i="12048" txt_f="12175">A total of 493 patients were screened from October 2002, to December 2005, with 487 subjects enrolled in the study (see online </offsets><ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-205060/-/DC1"><offsets xml_i="21188" xml_f="21208" txt_i="12175" txt_f="12195">supplementary figure</offsets></ext-link><offsets xml_i="21219" xml_f="21224" txt_i="12195" txt_f="12200"> S2).</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="21255" xml_f="21256" txt_i="12200" txt_f="12201">2</offsets></xref><offsets xml_i="21263" xml_f="21472" txt_i="12201" txt_f="12407"> Of the 258 patients with DAS28&gt;3.2 after the run-in period, 128 were randomised to infliximab and 130 to conventional treatment. Characteristics at randomisation were similar between the treatment groups (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB1"><offsets xml_i="21526" xml_f="21533" txt_i="12407" txt_f="12414">table 1</offsets></xref><offsets xml_i="21540" xml_f="21542" txt_i="12414" txt_f="12416">).</offsets></p><table-wrap id="ANNRHEUMDIS2013205060TB1" position="float"><label><offsets xml_i="21612" xml_f="21619" txt_i="12417" txt_f="12424">Table 1</offsets></label><caption><p><offsets xml_i="21639" xml_f="21677" txt_i="12424" txt_f="12462">Characteristics of randomised patients</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="21925" xml_f="21933" txt_i="12463" txt_f="12471">Variable</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="21979" xml_f="22007" txt_i="12471" txt_f="12499">Infliximab treatment (n=128)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="22053" xml_f="22083" txt_i="12499" txt_f="12529">Conventional treatment (n=130)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><offsets xml_i="22140" xml_f="22152" txt_i="12529" txt_f="12541">Women, n (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22185" xml_f="22192" txt_i="12542" txt_f="12549">97 (76)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22225" xml_f="22233" txt_i="12550" txt_f="12558">101 (78)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22275" xml_f="22305" txt_i="12559" txt_f="12589">Rheumatoid factor positive (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22338" xml_f="22345" txt_i="12590" txt_f="12597">88 (69)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22378" xml_f="22385" txt_i="12598" txt_f="12605">85 (65)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22427" xml_f="22449" txt_i="12606" txt_f="12628">Age (years), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22482" xml_f="22493" txt_i="12629" txt_f="12640">51.9 (13.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22526" xml_f="22537" txt_i="12641" txt_f="12652">53.7 (14.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22579" xml_f="22615" txt_i="12653" txt_f="12689">Symptom duration (months), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22648" xml_f="22658" txt_i="12690" txt_f="12700">10.1 (3.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22691" xml_f="22701" txt_i="12701" txt_f="12711">10.1 (3.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22743" xml_f="22759" txt_i="12712" txt_f="12728">DAS28, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22792" xml_f="22801" txt_i="12729" txt_f="12738">4.9 (1.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22834" xml_f="22843" txt_i="12739" txt_f="12748">4.8 (1.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="22885" xml_f="22900" txt_i="12749" txt_f="12764">HAQ*, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22933" xml_f="22942" txt_i="12765" txt_f="12774">0.9 (0.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="22975" xml_f="22984" txt_i="12775" txt_f="12784">1.0 (0.6)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23026" xml_f="23058" txt_i="12785" txt_f="12817">EQ-5D utility—UK preference set†</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23166" xml_f="23176" txt_i="12820" txt_f="12830"> Mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23209" xml_f="23220" txt_i="12831" txt_f="12842">0.51 (0.29)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23253" xml_f="23264" txt_i="12843" txt_f="12854">0.55 (0.27)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23306" xml_f="23325" txt_i="12855" txt_f="12874"> Median (25th–75th)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23358" xml_f="23374" txt_i="12875" txt_f="12891">0.62 (0.29–0.73)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23407" xml_f="23423" txt_i="12892" txt_f="12908">0.62 (0.52–0.73)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23465" xml_f="23481" txt_i="12909" txt_f="12925"> Minimum-maximum</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23514" xml_f="23527" txt_i="12926" txt_f="12939">−0.18 to 1.00</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23560" xml_f="23573" txt_i="12940" txt_f="12953">−0.24 to 1.00</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23615" xml_f="23647" txt_i="12954" txt_f="12986">EQ-5D utility—US preference set†</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23755" xml_f="23765" txt_i="12989" txt_f="12999"> Mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23798" xml_f="23809" txt_i="13000" txt_f="13011">0.65 (0.19)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23842" xml_f="23853" txt_i="13012" txt_f="13023">0.67 (0.18)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="23895" xml_f="23914" txt_i="13024" txt_f="13043"> Median (25th–75th)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23947" xml_f="23963" txt_i="13044" txt_f="13060">0.74 (0.53–0.80)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="23996" xml_f="24012" txt_i="13061" txt_f="13077">0.71 (0.60–0.81)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24054" xml_f="24070" txt_i="13078" txt_f="13094"> Minimum-maximum</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24103" xml_f="24112" txt_i="13095" txt_f="13104">0.20–1.00</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24145" xml_f="24154" txt_i="13105" txt_f="13114">0.17–1.00</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24196" xml_f="24212" txt_i="13115" txt_f="13131">Education, n (%)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24320" xml_f="24329" txt_i="13134" txt_f="13143"> ≤9 years</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24362" xml_f="24369" txt_i="13144" txt_f="13151">19 (15)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24402" xml_f="24409" txt_i="13152" txt_f="13159">26 (20)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24451" xml_f="24463" txt_i="13160" txt_f="13172"> 10–12 years</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24496" xml_f="24503" txt_i="13173" txt_f="13180">71 (55)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24536" xml_f="24543" txt_i="13181" txt_f="13188">63 (48)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24585" xml_f="24598" txt_i="13189" txt_f="13199"> &gt;12 years</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24631" xml_f="24638" txt_i="13200" txt_f="13207">30 (23)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24671" xml_f="24678" txt_i="13208" txt_f="13215">30 (23)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24720" xml_f="24728" txt_i="13216" txt_f="13224"> missing</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24761" xml_f="24766" txt_i="13225" txt_f="13230">8 (6)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24799" xml_f="24805" txt_i="13231" txt_f="13237">11 (8)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24847" xml_f="24862" txt_i="13238" txt_f="13253">Smoking‡, n (%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24895" xml_f="24902" txt_i="13254" txt_f="13261">33 (26)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="24935" xml_f="24942" txt_i="13262" txt_f="13269">30 (23)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="24984" xml_f="25009" txt_i="13270" txt_f="13295">Accumulated resource use </offsets><italic><offsets xml_i="25017" xml_f="25047" txt_i="13295" txt_f="13325">(60 days before randomisation)</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25164" xml_f="25188" txt_i="13328" txt_f="13352">Drug cost (€), mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25221" xml_f="25229" txt_i="13353" txt_f="13361">23 (7.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25262" xml_f="25270" txt_i="13362" txt_f="13370">22 (8.4)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25312" xml_f="25337" txt_i="13371" txt_f="13396">Healthcare use, mean (SD)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25445" xml_f="25480" txt_i="13399" txt_f="13434"> Non-primary outpatient care visits</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25513" xml_f="25522" txt_i="13435" txt_f="13444">2.9 (2.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25555" xml_f="25564" txt_i="13445" txt_f="13454">2.6 (1.9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25606" xml_f="25625" txt_i="13455" txt_f="13474"> Day surgery visits</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25658" xml_f="25667" txt_i="13475" txt_f="13484">0.1 (0.0)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25700" xml_f="25709" txt_i="13485" txt_f="13494">0.1 (0.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25751" xml_f="25766" txt_i="13495" txt_f="13510"> Inpatient days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25799" xml_f="25808" txt_i="13511" txt_f="13520">0.4 (2.4)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="25841" xml_f="25850" txt_i="13521" txt_f="13530">0.2 (2.0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="25892" xml_f="25901" txt_i="13531" txt_f="13540">Work loss</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26009" xml_f="26036" txt_i="13543" txt_f="13570"> Sick leave days, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26069" xml_f="26079" txt_i="13571" txt_f="13581">8.7 (18.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26112" xml_f="26122" txt_i="13582" txt_f="13592">9.6 (19.5)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26164" xml_f="26199" txt_i="13593" txt_f="13628"> Disability pension days, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26232" xml_f="26242" txt_i="13629" txt_f="13639">2.9 (11.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26275" xml_f="26285" txt_i="13640" txt_f="13650">4.8 (15.1)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="26327" xml_f="26349" txt_i="13651" txt_f="13673"> Total days, mean (SD)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26382" xml_f="26393" txt_i="13674" txt_f="13685">11.6 (20.2)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="26426" xml_f="26437" txt_i="13686" txt_f="13697">14.4 (22.7)</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="26487" xml_f="26621" txt_i="13698" txt_f="13832">*Missing HAQ information for four patients in the infliximab treatment group and for two patients in the conventional treatment group.</offsets></p></fn><fn><p><offsets xml_i="26637" xml_f="26770" txt_i="13833" txt_f="13966">†Missing EQ-5D information for 21 patients in the infliximab treatment group and for 13 patients in the conventional treatment group.</offsets></p></fn><fn><p><offsets xml_i="26786" xml_f="26925" txt_i="13967" txt_f="14106">‡Missing smoking information for five patients in the infliximab treatment group and for four patients in the conventional treatment group.</offsets></p></fn><fn><p><offsets xml_i="26941" xml_f="27185" txt_i="14107" txt_f="14351">DAS28, 28-joint count disease-activity score; EQ-5D, EuroQol 5-Dimensions; HAQ, Health Assessment Questionnaire; Infliximab treatment, Infliximab plus methotrexate; Conventional treatment, Sulfasalazine and hydroxychloroquine plus methotrexate.</offsets></p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title><offsets xml_i="27252" xml_f="27257" txt_i="14353" txt_f="14358">Costs</offsets></title><p><italic><offsets xml_i="27276" xml_f="27299" txt_i="14359" txt_f="14382">Drug and healthcare use</offsets></italic><offsets xml_i="27308" xml_f="27516" txt_i="14382" txt_f="14590">: Due to the high cost of infliximab, the mean total drug cost was higher in the infliximab than the conventional treatment group (€19 215 vs €4710; adjusted mean difference €14 280; 95% CI 12 269 to 16 101; </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="27570" xml_f="27577" txt_i="14590" txt_f="14597">table 2</offsets></xref><offsets xml_i="27584" xml_f="27596" txt_i="14597" txt_f="14609"> and online </offsets><ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-205060/-/DC1"><offsets xml_i="27713" xml_f="27733" txt_i="14609" txt_f="14629">supplementary figure</offsets></ext-link><offsets xml_i="27744" xml_f="28057" txt_i="14629" txt_f="14942"> S3). Furthermore, infliximab was administered at the hospital, and patients in the infliximab group had more rheumatologist visits and borderline more inpatient days, resulting in higher healthcare costs than the conventional treatment group (€8272 vs €5653; adjusted mean difference €2676; 95% CI 1425 to 4058).</offsets></p><table-wrap id="ANNRHEUMDIS2013205060TB2" position="float"><label><offsets xml_i="28127" xml_f="28134" txt_i="14943" txt_f="14950">Table 2</offsets></label><caption><p><offsets xml_i="28154" xml_f="28244" txt_i="14950" txt_f="15040">Mean accumulated costs and quality-adjusted life-years (QALYs) over 21 months of follow-up</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="char" char=" " span="1"></col><col align="char" char=" " span="1"></col></colgroup><thead valign="bottom"><tr><th align="left" rowspan="2" colspan="1"><offsets xml_i="28609" xml_f="28623" txt_i="15041" txt_f="15055">Cost component</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="28669" xml_f="28689" txt_i="15055" txt_f="15075">Infliximab treatment</offsets></th><th align="left" colspan="2" rowspan="1"><offsets xml_i="28735" xml_f="28757" txt_i="15075" txt_f="15097">Conventional treatment</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="28803" xml_f="28832" txt_i="15097" txt_f="15126">Adjusted difference (95% CI†)</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="28887" xml_f="28900" txt_i="15126" txt_f="15139">Resource use*</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="28946" xml_f="28960" txt_i="15139" txt_f="15153">Mean cost (SD)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="29006" xml_f="29019" txt_i="15153" txt_f="15166">Resource use*</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="29065" xml_f="29079" txt_i="15166" txt_f="15180">Mean cost (SD)</offsets></th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><italic><offsets xml_i="29144" xml_f="29167" txt_i="15180" txt_f="15203">Drug use, % of patients</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29383" xml_f="29392" txt_i="15209" txt_f="15218">Biologics</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29599" xml_f="29610" txt_i="15224" txt_f="15235"> Infliximab</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29643" xml_f="29646" txt_i="15236" txt_f="15239">95%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29679" xml_f="29693" txt_i="15240" txt_f="15254">€16 870 (8272)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29726" xml_f="29728" txt_i="15255" txt_f="15257">8%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29761" xml_f="29773" txt_i="15258" txt_f="15270">€1080 (3831)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29806" xml_f="29832" txt_i="15271" txt_f="15297">€15 729 (14 065 to 17 178)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="29874" xml_f="29885" txt_i="15298" txt_f="15309"> Etanercept</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29918" xml_f="29921" txt_i="15310" txt_f="15313">13%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29954" xml_f="29966" txt_i="15314" txt_f="15326">€1901 (5595)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="29999" xml_f="30002" txt_i="15327" txt_f="15330">16%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30035" xml_f="30047" txt_i="15331" txt_f="15343">€2281 (5854)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30080" xml_f="30100" txt_i="15344" txt_f="15364">−€525 (−1792 to 876)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30142" xml_f="30153" txt_i="15365" txt_f="15376"> Adalimumab</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30186" xml_f="30188" txt_i="15377" txt_f="15379">2%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30221" xml_f="30232" txt_i="15380" txt_f="15391">€229 (1779)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30265" xml_f="30267" txt_i="15392" txt_f="15394">5%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30300" xml_f="30311" txt_i="15395" txt_f="15406">€659 (3144)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30344" xml_f="30364" txt_i="15407" txt_f="15427">−€462 (−1180 to 107)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30406" xml_f="30416" txt_i="15428" txt_f="15438"> Rituximab</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30449" xml_f="30451" txt_i="15439" txt_f="15441">0%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30484" xml_f="30485" txt_i="15442" txt_f="15443">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30518" xml_f="30520" txt_i="15444" txt_f="15446">1%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30553" xml_f="30562" txt_i="15447" txt_f="15456">€44 (503)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30595" xml_f="30613" txt_i="15457" txt_f="15475">−€54 (−102 to −39)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30655" xml_f="30674" txt_i="15476" txt_f="15495">Conventional DMARDs</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="30881" xml_f="30894" txt_i="15501" txt_f="15514"> Methotrexate</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30927" xml_f="30931" txt_i="15515" txt_f="15519">100%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="30964" xml_f="30973" txt_i="15520" txt_f="15529">€105 (34)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31006" xml_f="31010" txt_i="15530" txt_f="15534">100%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31043" xml_f="31052" txt_i="15535" txt_f="15544">€113 (25)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31085" xml_f="31099" txt_i="15545" txt_f="15559">−€8 (−15 to 0)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31141" xml_f="31155" txt_i="15560" txt_f="15574"> Sulfasalazine</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31188" xml_f="31190" txt_i="15575" txt_f="15577">7%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31223" xml_f="31231" txt_i="15578" txt_f="15586">€12 (53)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31264" xml_f="31267" txt_i="15587" txt_f="15590">96%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31300" xml_f="31310" txt_i="15591" txt_f="15601">€206 (139)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31343" xml_f="31363" txt_i="15602" txt_f="15622">−€192 (−216 to −166)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31405" xml_f="31406" txt_i="15623" txt_f="15624"> </offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31439" xml_f="31441" txt_i="15625" txt_f="15627">5%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31474" xml_f="31481" txt_i="15628" txt_f="15635">€3 (14)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31514" xml_f="31517" txt_i="15636" txt_f="15639">89%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31550" xml_f="31558" txt_i="15640" txt_f="15648">€78 (59)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31591" xml_f="31608" txt_i="15649" txt_f="15666">−€74 (−85 to −65)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31650" xml_f="31664" txt_i="15667" txt_f="15681"> Ciclosporin A</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31697" xml_f="31699" txt_i="15682" txt_f="15684">1%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31732" xml_f="31741" txt_i="15685" txt_f="15694">€18 (207)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31774" xml_f="31776" txt_i="15695" txt_f="15697">9%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31809" xml_f="31819" txt_i="15698" txt_f="15708">€162 (682)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31852" xml_f="31871" txt_i="15709" txt_f="15728">−€123 (−254 to −38)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="31913" xml_f="31925" txt_i="15729" txt_f="15741"> Azathioprin</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31958" xml_f="31960" txt_i="15742" txt_f="15744">1%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="31993" xml_f="32000" txt_i="15745" txt_f="15752">€2 (22)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32033" xml_f="32035" txt_i="15753" txt_f="15755">1%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32068" xml_f="32074" txt_i="15756" txt_f="15762">€1 (8)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32107" xml_f="32119" txt_i="15763" txt_f="15775">€1 (−2 to 9)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32161" xml_f="32173" txt_i="15776" txt_f="15788"> Leflunomide</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32206" xml_f="32208" txt_i="15789" txt_f="15791">1%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32241" xml_f="32248" txt_i="15792" txt_f="15799">€3 (34)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32281" xml_f="32283" txt_i="15800" txt_f="15802">3%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32316" xml_f="32323" txt_i="15803" txt_f="15810">€6 (36)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32356" xml_f="32370" txt_i="15811" txt_f="15825">−€2 (−9 to 10)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32412" xml_f="32434" txt_i="15826" txt_f="15848"> Chloroquine phosphate</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32467" xml_f="32469" txt_i="15849" txt_f="15851">0%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32502" xml_f="32503" txt_i="15852" txt_f="15853">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32536" xml_f="32538" txt_i="15854" txt_f="15856">5%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32571" xml_f="32578" txt_i="15857" txt_f="15864">€8 (43)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32611" xml_f="32626" txt_i="15865" txt_f="15880">−€9 (−21 to −3)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32668" xml_f="32673" txt_i="15881" txt_f="15886">Other</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="32880" xml_f="32896" txt_i="15892" txt_f="15908"> Glucocorticoids</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32929" xml_f="32932" txt_i="15909" txt_f="15912">16%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="32965" xml_f="32972" txt_i="15913" txt_f="15920">€6 (18)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33005" xml_f="33008" txt_i="15921" txt_f="15924">22%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33041" xml_f="33048" txt_i="15925" txt_f="15932">€9 (20)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33081" xml_f="33094" txt_i="15933" txt_f="15946">−€3 (−7 to 2)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33136" xml_f="33143" txt_i="15947" txt_f="15954"> NSAIDs</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33176" xml_f="33179" txt_i="15955" txt_f="15958">77%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33212" xml_f="33220" txt_i="15959" txt_f="15967">€65 (60)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33253" xml_f="33256" txt_i="15968" txt_f="15971">68%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33289" xml_f="33297" txt_i="15972" txt_f="15980">€61 (62)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33330" xml_f="33344" txt_i="15981" txt_f="15995">€2 (−13 to 16)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33386" xml_f="33400" txt_i="15996" txt_f="16010">Total drug use</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33433" xml_f="33437" txt_i="16011" txt_f="16015">100%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33470" xml_f="33484" txt_i="16016" txt_f="16030">€19 215 (7940)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33517" xml_f="33521" txt_i="16031" txt_f="16035">100%</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33554" xml_f="33566" txt_i="16036" txt_f="16048">€4710 (7477)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33599" xml_f="33625" txt_i="16049" txt_f="16075">€14 280 (12 269 to 16 101)</offsets></td></tr><tr><td rowspan="1" colspan="1"><italic><offsets xml_i="33675" xml_f="33689" txt_i="16076" txt_f="16090">Healthcare use</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="33905" xml_f="33939" txt_i="16096" txt_f="16130">Non-primary outpatient care visits</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="33972" xml_f="33979" txt_i="16131" txt_f="16138">20 (12)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34012" xml_f="34024" txt_i="16139" txt_f="16151">€6151 (4070)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34057" xml_f="34064" txt_i="16152" txt_f="16159">16 (10)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34097" xml_f="34109" txt_i="16160" txt_f="16172">€4372 (2625)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34142" xml_f="34161" txt_i="16173" txt_f="16192">€1749 (924 to 2672)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34203" xml_f="34218" txt_i="16193" txt_f="16208"> Rheumatologist</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34251" xml_f="34258" txt_i="16209" txt_f="16216">19 (12)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34291" xml_f="34303" txt_i="16217" txt_f="16229">€5687 (3882)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34336" xml_f="34342" txt_i="16230" txt_f="16236">15 (9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34375" xml_f="34387" txt_i="16237" txt_f="16249">€3823 (2368)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34420" xml_f="34440" txt_i="16250" txt_f="16270">€1813 (1037 to 2654)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34482" xml_f="34500" txt_i="16271" txt_f="16289"> Other specialists</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34533" xml_f="34542" txt_i="16290" txt_f="16299">1.5 (1.9)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34575" xml_f="34585" txt_i="16300" txt_f="16310">€463 (690)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34618" xml_f="34627" txt_i="16311" txt_f="16320">1.7 (2.3)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34660" xml_f="34670" txt_i="16321" txt_f="16331">€548 (801)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34703" xml_f="34721" txt_i="16332" txt_f="16350">−€64 (−249 to 116)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="34763" xml_f="34785" txt_i="16351" txt_f="16373">Day surgery procedures</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34818" xml_f="34827" txt_i="16374" txt_f="16383">0.9 (2.1)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34860" xml_f="34870" txt_i="16384" txt_f="16394">€394 (866)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34903" xml_f="34912" txt_i="16395" txt_f="16404">0.9 (1.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34945" xml_f="34955" txt_i="16405" txt_f="16415">€319 (495)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="34988" xml_f="35004" txt_i="16416" txt_f="16432">€77 (−73 to 271)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35046" xml_f="35069" txt_i="16433" txt_f="16456">Hospital admission days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35102" xml_f="35111" txt_i="16457" txt_f="16466">2.8 (7.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35144" xml_f="35156" txt_i="16467" txt_f="16479">€1726 (4211)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35189" xml_f="35198" txt_i="16480" txt_f="16489">1.1 (3.5)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35231" xml_f="35242" txt_i="16490" txt_f="16501">€961 (3070)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35275" xml_f="35293" txt_i="16502" txt_f="16520">€850 (−42 to 1742)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35335" xml_f="35378" txt_i="16521" txt_f="16564"> Hip/knee prosthesis procedures, n patients</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35411" xml_f="35417" txt_i="16565" txt_f="16571">4 (3%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35450" xml_f="35461" txt_i="16572" txt_f="16583">€258 (1446)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35494" xml_f="35500" txt_i="16584" txt_f="16590">2 (2%)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35533" xml_f="35544" txt_i="16591" txt_f="16602">€127 (1023)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35577" xml_f="35595" txt_i="16603" txt_f="16621">€170 (−127 to 499)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35637" xml_f="35657" txt_i="16622" txt_f="16642">Total healthcare use</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="35723" xml_f="35735" txt_i="16644" txt_f="16656">€8272 (6288)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="35801" xml_f="35813" txt_i="16658" txt_f="16670">€5653 (4233)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="35846" xml_f="35866" txt_i="16671" txt_f="16691">€2676 (1425 to 4058)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="35908" xml_f="35936" txt_i="16692" txt_f="16720">Healthcare perspective costs</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="36002" xml_f="36018" txt_i="16722" txt_f="16738">€27 487 (10 101)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="36084" xml_f="36098" txt_i="16740" txt_f="16754">€10 364 (9214)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36131" xml_f="36157" txt_i="16755" txt_f="16781">€16 956 (14 647 to 19 162)</offsets></td></tr><tr><td rowspan="1" colspan="1"><italic><offsets xml_i="36207" xml_f="36216" txt_i="16782" txt_f="16791">Work loss</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36432" xml_f="36452" txt_i="16797" txt_f="16817">Human capital method</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36659" xml_f="36675" txt_i="16823" txt_f="16839"> Sick leave days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36708" xml_f="36717" txt_i="16840" txt_f="16849">194 (223)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36750" xml_f="36766" txt_i="16850" txt_f="16866">€26 954 (30 914)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36799" xml_f="36808" txt_i="16867" txt_f="16876">144 (200)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36841" xml_f="36857" txt_i="16877" txt_f="16893">€20 027 (27 716)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="36890" xml_f="36913" txt_i="16894" txt_f="16917">€4876 (−1443 to 11 373)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="36955" xml_f="36979" txt_i="16918" txt_f="16942"> Disability pension days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37012" xml_f="37020" txt_i="16943" txt_f="16951">49 (138)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37053" xml_f="37067" txt_i="16952" txt_f="16966">€6849 (19 104)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37100" xml_f="37108" txt_i="16967" txt_f="16975">66 (165)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37141" xml_f="37155" txt_i="16976" txt_f="16990">€9192 (22 937)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37188" xml_f="37209" txt_i="16991" txt_f="17012">−€915 (−5338 to 4144)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37251" xml_f="37271" txt_i="17013" txt_f="17033">Total work loss days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37304" xml_f="37313" txt_i="17034" txt_f="17043">244 (246)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37346" xml_f="37362" txt_i="17044" txt_f="17060">€33 804 (34 115)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37395" xml_f="37404" txt_i="17061" txt_f="17070">211 (251)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37437" xml_f="37453" txt_i="17071" txt_f="17087">€29 220 (34 764)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37486" xml_f="37509" txt_i="17088" txt_f="17111">€3961 (−3986 to 11 850)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37551" xml_f="37571" txt_i="17112" txt_f="17132">Friction cost method</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="37778" xml_f="37794" txt_i="17138" txt_f="17154"> Sick leave days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37827" xml_f="37834" txt_i="17155" txt_f="17162">87 (76)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37867" xml_f="37883" txt_i="17163" txt_f="17179">€12 093 (10 552)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37916" xml_f="37923" txt_i="17180" txt_f="17187">64 (77)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="37956" xml_f="37970" txt_i="17188" txt_f="17202">€8935 (10 715)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38003" xml_f="38022" txt_i="17203" txt_f="17222">€2246 (−79 to 4546)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38064" xml_f="38088" txt_i="17223" txt_f="17247"> Disability pension days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38121" xml_f="38128" txt_i="17248" txt_f="17255">18 (46)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38161" xml_f="38173" txt_i="17256" txt_f="17268">€2504 (6333)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38206" xml_f="38213" txt_i="17269" txt_f="17276">22 (52)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38246" xml_f="38258" txt_i="17277" txt_f="17289">€3083 (7185)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38291" xml_f="38312" txt_i="17290" txt_f="17311">−€112 (−1637 to 1382)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38354" xml_f="38374" txt_i="17312" txt_f="17332">Total work loss days</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38407" xml_f="38415" txt_i="17333" txt_f="17341">105 (80)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38448" xml_f="38464" txt_i="17342" txt_f="17358">€14 597 (11 098)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38497" xml_f="38504" txt_i="17359" txt_f="17366">87 (86)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38537" xml_f="38553" txt_i="17367" txt_f="17383">€12 018 (11 972)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="38586" xml_f="38606" txt_i="17384" txt_f="17404">€2134 (−284 to 4535)</offsets></td></tr><tr><td rowspan="1" colspan="1"><italic><offsets xml_i="38656" xml_f="38676" txt_i="17405" txt_f="17425">Total societal costs</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="38892" xml_f="38913" txt_i="17431" txt_f="17452"> Human capital method</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="38979" xml_f="38995" txt_i="17454" txt_f="17470">€61 291 (36 201)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="39061" xml_f="39077" txt_i="17472" txt_f="17488">€39 584 (38 052)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39110" xml_f="39136" txt_i="17489" txt_f="17515">€20 916 (12 800 to 28 660)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39178" xml_f="39199" txt_i="17516" txt_f="17537"> Friction cost method</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="39265" xml_f="39281" txt_i="17539" txt_f="17555">€42 084 (15 112)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="39347" xml_f="39363" txt_i="17557" txt_f="17573">€22 382 (17 118)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39396" xml_f="39422" txt_i="17574" txt_f="17600">€19 090 (15 564 to 22 252)</offsets></td></tr><tr><td rowspan="1" colspan="1"><italic><offsets xml_i="39472" xml_f="39489" txt_i="17601" txt_f="17618">Accumulated QALYs</offsets></italic></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39705" xml_f="39714" txt_i="17624" txt_f="17633"> UK EQ-5D</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="39747" xml_f="39758" txt_i="17634" txt_f="17645">1.10 (0.40)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="39824" xml_f="39835" txt_i="17647" txt_f="17658">1.12 (0.39)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="39901" xml_f="39921" txt_i="17660" txt_f="17680">0.01 (−0.07 to 0.08)</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="39963" xml_f="39972" txt_i="17681" txt_f="17690"> US EQ-5D</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="40005" xml_f="40016" txt_i="17691" txt_f="17702">1.27 (0.27)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="40082" xml_f="40093" txt_i="17704" txt_f="17715">1.28 (0.27)</offsets></td><td rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"><offsets xml_i="40159" xml_f="40179" txt_i="17717" txt_f="17737">0.01 (−0.05 to 0.06)</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="40229" xml_f="40290" txt_i="17738" txt_f="17799">*Mean (SD) if not otherwise stated (normal-based estimation).</offsets></p></fn><fn><p><offsets xml_i="40306" xml_f="40356" txt_i="17800" txt_f="17850">†CIs estimated using non-parametric bootstrapping.</offsets></p></fn><fn><p><offsets xml_i="40372" xml_f="40490" txt_i="17851" txt_f="17969">DMARD, disease-modifying antirheumatic drug; EQ-5D, EuroQol 5-Dimensions; NSAID, non-steroidal anti-inflammatory drug.</offsets></p></fn></table-wrap-foot></table-wrap><p><italic><offsets xml_i="40541" xml_f="40550" txt_i="17970" txt_f="17979">Work loss</offsets></italic><offsets xml_i="40559" xml_f="40791" txt_i="17979" txt_f="18211">: No between-group difference in productivity losses was detected using the human capital method comparing the infliximab and conventional treatment group (€33 804 vs €29 220; adjusted mean difference €3961; 95% CI −3986 to 11 850).</offsets></p><p><italic><offsets xml_i="40806" xml_f="40817" txt_i="18212" txt_f="18223">Total costs</offsets></italic><offsets xml_i="40826" xml_f="41113" txt_i="18223" txt_f="18510">: Total costs were higher in the infliximab than the conventional treatment group from the healthcare (€27 487 vs €10 364; adjusted mean difference €16 956; 95% CI 14 647 to 19 162) and societal perspective (€61 291 vs €39 584; adjusted mean difference €20 916; 95% CI 12 800 to 28 660).</offsets></p></sec><sec id="s3c"><title><offsets xml_i="41144" xml_f="41161" txt_i="18512" txt_f="18529">Utility and QALYs</offsets></title><p><offsets xml_i="41172" xml_f="41326" txt_i="18530" txt_f="18684">Using the UK EQ-5D preference set, the mean (SD) utility at 21 months was 0.64 (0.28) in the infliximab and 0.68 (0.25) in the conventional treatment arm.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="41357" xml_f="41358" txt_i="18684" txt_f="18685">4</offsets></xref><offsets xml_i="41365" xml_f="41547" txt_i="18685" txt_f="18867"> Mean accumulated QALYs were 1.10 in the infliximab and 1.12 in the conventional treatment group (adjusted mean difference favouring infliximab treatment 0.01; 95% CI −0.07 to 0.08; </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="41601" xml_f="41608" txt_i="18867" txt_f="18874">table 2</offsets></xref><offsets xml_i="41615" xml_f="41617" txt_i="18874" txt_f="18876">).</offsets></p></sec><sec id="s3d"><title><offsets xml_i="41648" xml_f="41685" txt_i="18878" txt_f="18915">Incremental cost-effectiveness ratios</offsets></title><p><offsets xml_i="41696" xml_f="41855" txt_i="18916" txt_f="19075">From the societal perspective, the incremental cost-effectiveness ratio for the infliximab, as compared to the conventional treatment was €2 404 197 per QALY (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB3"><offsets xml_i="41909" xml_f="41916" txt_i="19075" txt_f="19082">table 3</offsets></xref><offsets xml_i="41923" xml_f="41992" txt_i="19082" txt_f="19151">). From the healthcare perspective the cost was €1 948 919 per QALY (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB3"><offsets xml_i="42046" xml_f="42053" txt_i="19151" txt_f="19158">table 3</offsets></xref><offsets xml_i="42060" xml_f="42145" txt_i="19158" txt_f="19243">). The variation in incremental cost was lower when only including healthcare costs (</offsets><xref ref-type="fig" rid="ANNRHEUMDIS2013205060F1"><offsets xml_i="42196" xml_f="42204" txt_i="19243" txt_f="19251">figure 1</offsets></xref><offsets xml_i="42211" xml_f="42213" txt_i="19251" txt_f="19253">).</offsets></p><table-wrap id="ANNRHEUMDIS2013205060TB3" position="float"><label><offsets xml_i="42283" xml_f="42290" txt_i="19254" txt_f="19261">Table 3</offsets></label><caption><p><offsets xml_i="42310" xml_f="42427" txt_i="19261" txt_f="19378">Incremental costs, effects and cost-effectiveness ratios of the infliximab versus the conventional treatment strategy</offsets></p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col><col align="left" span="1"></col></colgroup><thead valign="bottom"><tr><th rowspan="2" align="left" colspan="1"><offsets xml_i="42840" xml_f="42858" txt_i="19379" txt_f="19397">Perspective/method</offsets></th><th rowspan="2" align="left" colspan="1"><offsets xml_i="42904" xml_f="42905" txt_i="19397" txt_f="19398">n</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="42951" xml_f="42971" txt_i="19398" txt_f="19418">Incremental cost (€)</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="43017" xml_f="43042" txt_i="19418" txt_f="19443">Incremental effect (QALY)</offsets></th><th align="left" rowspan="2" colspan="1"><offsets xml_i="43088" xml_f="43105" txt_i="19443" txt_f="19460">ICER (€ per QALY)</offsets></th><th align="left" colspan="3" rowspan="1"><offsets xml_i="43151" xml_f="43198" txt_i="19460" txt_f="19507">% Cost-effective at willingness-to-pay per QALY</offsets></th></tr><tr><th align="left" rowspan="1" colspan="1"><offsets xml_i="43253" xml_f="43264" txt_i="19507" txt_f="19518">€50 000 (%)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="43310" xml_f="43322" txt_i="19518" txt_f="19530">€100 000 (%)</offsets></th><th align="left" rowspan="1" colspan="1"><offsets xml_i="43368" xml_f="43382" txt_i="19530" txt_f="19544">€1 000 000 (%)</offsets></th></tr></thead><tbody><tr><td colspan="8" rowspan="1"><italic><offsets xml_i="43447" xml_f="43467" txt_i="19544" txt_f="19564">Societal perspective</offsets></italic></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="43518" xml_f="43541" txt_i="19565" txt_f="19588">Overall (main analysis)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43574" xml_f="43577" txt_i="19589" txt_f="19592">258</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43610" xml_f="43616" txt_i="19593" txt_f="19599">20 916</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43649" xml_f="43654" txt_i="19600" txt_f="19605">0.009</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43687" xml_f="43696" txt_i="19606" txt_f="19615">2 404 197</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43729" xml_f="43730" txt_i="19616" txt_f="19617">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43763" xml_f="43764" txt_i="19618" txt_f="19619">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43797" xml_f="43799" txt_i="19620" txt_f="19622">38</offsets></td></tr><tr><td colspan="8" rowspan="1"><offsets xml_i="43841" xml_f="43861" txt_i="19623" txt_f="19643">Sensitivity analysis</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="43903" xml_f="43924" txt_i="19644" txt_f="19665"> Friction cost method</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43957" xml_f="43960" txt_i="19666" txt_f="19669">258</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="43993" xml_f="43999" txt_i="19670" txt_f="19676">19 090</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44032" xml_f="44037" txt_i="19677" txt_f="19682">0.009</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44070" xml_f="44079" txt_i="19683" txt_f="19692">2 194 250</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44112" xml_f="44113" txt_i="19693" txt_f="19694">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44146" xml_f="44147" txt_i="19695" txt_f="19696">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44180" xml_f="44182" txt_i="19697" txt_f="19699">39</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="44224" xml_f="44240" txt_i="19700" txt_f="19716"> US EQ-5D tariff</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44273" xml_f="44276" txt_i="19717" txt_f="19720">258</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44309" xml_f="44315" txt_i="19721" txt_f="19727">20 916</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44348" xml_f="44353" txt_i="19728" txt_f="19733">0.005</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44386" xml_f="44395" txt_i="19734" txt_f="19743">3 926 628</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44428" xml_f="44429" txt_i="19744" txt_f="19745">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44462" xml_f="44463" txt_i="19746" txt_f="19747">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44496" xml_f="44498" txt_i="19748" txt_f="19750">28</offsets></td></tr><tr><td colspan="8" rowspan="1"><italic><offsets xml_i="44548" xml_f="44570" txt_i="19751" txt_f="19773">Healthcare perspective</offsets></italic></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="44621" xml_f="44644" txt_i="19774" txt_f="19797">Overall (main analysis)</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44677" xml_f="44680" txt_i="19798" txt_f="19801">258</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44713" xml_f="44719" txt_i="19802" txt_f="19808">16 956</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44752" xml_f="44757" txt_i="19809" txt_f="19814">0.009</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44790" xml_f="44799" txt_i="19815" txt_f="19824">1 948 919</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44832" xml_f="44833" txt_i="19825" txt_f="19826">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44866" xml_f="44867" txt_i="19827" txt_f="19828">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="44900" xml_f="44902" txt_i="19829" txt_f="19831">41</offsets></td></tr><tr><td colspan="8" rowspan="1"><offsets xml_i="44944" xml_f="44964" txt_i="19832" txt_f="19852">Sensitivity analysis</offsets></td></tr><tr><td rowspan="1" colspan="1"><offsets xml_i="45006" xml_f="45022" txt_i="19853" txt_f="19869"> US EQ-5D tariff</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45055" xml_f="45058" txt_i="19870" txt_f="19873">258</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45091" xml_f="45097" txt_i="19874" txt_f="19880">16 956</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45130" xml_f="45135" txt_i="19881" txt_f="19886">0.005</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45168" xml_f="45177" txt_i="19887" txt_f="19896">3 183 050</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45210" xml_f="45211" txt_i="19897" txt_f="19898">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45244" xml_f="45245" txt_i="19899" txt_f="19900">0</offsets></td><td rowspan="1" colspan="1"><offsets xml_i="45278" xml_f="45280" txt_i="19901" txt_f="19903">32</offsets></td></tr></tbody></table><table-wrap-foot><fn><p><offsets xml_i="45330" xml_f="45436" txt_i="19904" txt_f="20010">EQ-5D, EuroQol 5-Dimensions; ICER, Incremental cost-effectiveness ratio; QALY, Quality-adjusted life-year.</offsets></p></fn></table-wrap-foot></table-wrap><fig id="ANNRHEUMDIS2013205060F1" position="float"><label><offsets xml_i="45534" xml_f="45542" txt_i="20011" txt_f="20019">Figure 1</offsets></label><caption><p><offsets xml_i="45562" xml_f="45719" txt_i="20019" txt_f="20176">Bootstrapped incremental cost-effectiveness ratio plots by societal and healthcare perspective for the infliximab versus the conventional treatment strategy.</offsets></p></caption><graphic xlink:href="annrheumdis-2013-205060f01"></graphic></fig><p><offsets xml_i="45801" xml_f="45895" txt_i="20177" txt_f="20271">No bootstrap samples were cost-saving from either the societal or the healthcare perspective (</offsets><xref ref-type="fig" rid="ANNRHEUMDIS2013205060F1"><offsets xml_i="45946" xml_f="45954" txt_i="20271" txt_f="20279">figure 1</offsets></xref><offsets xml_i="45961" xml_f="46266" txt_i="20279" txt_f="20584">). With increasing willingness to pay per QALY, the probability of infliximab treatment being cost-effective compared to conventional therapy increased slowly, and was 0% at €50 000 per QALY from both perspectives, and 38% from the societal and 41% from the healthcare perspective at €1 000 000 per QALY (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB3"><offsets xml_i="46320" xml_f="46327" txt_i="20584" txt_f="20591">table 3</offsets></xref><offsets xml_i="46334" xml_f="46339" txt_i="20591" txt_f="20596"> and </offsets><xref ref-type="fig" rid="ANNRHEUMDIS2013205060F2"><offsets xml_i="46390" xml_f="46398" txt_i="20596" txt_f="20604">figure 2</offsets></xref><offsets xml_i="46405" xml_f="46407" txt_i="20604" txt_f="20606">).</offsets></p><fig id="ANNRHEUMDIS2013205060F2" position="float"><label><offsets xml_i="46469" xml_f="46477" txt_i="20607" txt_f="20615">Figure 2</offsets></label><caption><p><offsets xml_i="46497" xml_f="46638" txt_i="20615" txt_f="20756">Cost-effectiveness acceptability curves by societal and healthcare perspective for the infliximab versus the conventional treatment strategy.</offsets></p></caption><graphic xlink:href="annrheumdis-2013-205060f02"></graphic></fig></sec><sec id="s3e"><title><offsets xml_i="46744" xml_f="46764" txt_i="20758" txt_f="20778">Sensitivity analysis</offsets></title><sec id="s3e1"><title><offsets xml_i="46794" xml_f="46799" txt_i="20779" txt_f="20784">Costs</offsets></title><p><offsets xml_i="46810" xml_f="47155" txt_i="20785" txt_f="21130">Using the friction cost method for valuation of productivity losses, the infliximab group had borderline higher productivity losses (€14 597 vs €12 018; adjusted mean difference €2134; 95% CI −284 to 4535), and (as with the human capital method) higher total costs (€42 084 vs €22 382; adjusted mean difference €19 090; 95% CI 15 564 to 22 252; </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="47209" xml_f="47216" txt_i="21130" txt_f="21137">table 2</offsets></xref><offsets xml_i="47223" xml_f="47263" txt_i="21137" txt_f="21177">) than the conventional treatment group.</offsets></p></sec><sec id="s3e2"><title><offsets xml_i="47295" xml_f="47300" txt_i="21179" txt_f="21184">QALYs</offsets></title><p><offsets xml_i="47311" xml_f="47526" txt_i="21185" txt_f="21400">Mean accumulated QALYs using the US EQ-5D preference set were 1.27 in the infliximab and 1.28 in the conventional treatment group (adjusted mean difference favouring infliximab treatment 0.01; 95% CI −0.05 to 0.06; </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="47580" xml_f="47587" txt_i="21400" txt_f="21407">table 2</offsets></xref><offsets xml_i="47594" xml_f="47596" txt_i="21407" txt_f="21409">).</offsets></p></sec><sec id="s3e3"><title><offsets xml_i="47628" xml_f="47665" txt_i="21411" txt_f="21448">Incremental cost-effectiveness ratios</offsets></title><p><offsets xml_i="47676" xml_f="47915" txt_i="21449" txt_f="21688">Using the friction cost method for valuation of productivity losses, the adjusted incremental cost was similar to that found by the human capital method, resulting in a similar incremental cost-effectiveness ratio as in the main analysis (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="47969" xml_f="47977" txt_i="21688" txt_f="21696">tables 2</offsets></xref><offsets xml_i="47984" xml_f="47989" txt_i="21696" txt_f="21701"> and </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB3"><offsets xml_i="48043" xml_f="48044" txt_i="21701" txt_f="21702">3</offsets></xref><offsets xml_i="48051" xml_f="48053" txt_i="21702" txt_f="21704">).</offsets></p><p><offsets xml_i="48060" xml_f="48364" txt_i="21705" txt_f="22009">Applying the US, rather than the UK, EQ-5D tariff, the adjusted incremental effect between the treatment groups decreased, resulting in higher incremental cost-effectiveness ratios from the healthcare (€3 183 050 per QALY) and societal perspective (€3 926 628 per QALY), as compared to the main analysis.</offsets></p></sec></sec><sec id="s3f"><title><offsets xml_i="48401" xml_f="48420" txt_i="22012" txt_f="22031">Unadjusted analysis</offsets></title><p><offsets xml_i="48431" xml_f="48730" txt_i="22032" txt_f="22331">Unadjusted analyses resulted in mean between-group cost differences similar to those found in the adjusted assessments. The point estimate for the mean effect difference was negative in all unadjusted analyses, resulting in a low probability of infliximab treatment being cost-effective (see online </offsets><ext-link ext-link-type="uri" xlink:href="http://ard.bmj.com/lookup/suppl/doi:10.1136/annrheumdis-2013-205060/-/DC1"><offsets xml_i="48847" xml_f="48867" txt_i="22331" txt_f="22351">supplementary figure</offsets></ext-link><offsets xml_i="48878" xml_f="48905" txt_i="22351" txt_f="22378">s S4 and S5, and table S1).</offsets></p></sec></sec><sec sec-type="discussion" id="s4"><title><offsets xml_i="48963" xml_f="48973" txt_i="22381" txt_f="22391">Discussion</offsets></title><sec id="s4a"><title><offsets xml_i="49002" xml_f="49015" txt_i="22392" txt_f="22405">Main findings</offsets></title><p><offsets xml_i="49026" xml_f="49572" txt_i="22406" txt_f="22952">In this register-enriched randomised controlled trial of early, methotrexate-refractory RA, the addition of infliximab, as compared to sulfasalazine and hydroxychloroquine, resulted in higher drug and healthcare costs, while no differences were detected in productivity losses or QALYs over 21 months. Irrespective of study perspective, compared to the conventional alternative, the infliximab strategy was not found to be cost-effective at willingness-to-pay levels generally considered acceptable (US$50 000–100 000 or £20 000–30 000 per QALY).</offsets><xref rid="R21" ref-type="bibr"><offsets xml_i="49604" xml_f="49606" txt_i="22952" txt_f="22954">21</offsets></xref><offsets xml_i="49613" xml_f="49614" txt_i="22954" txt_f="22955">
</offsets><xref rid="R22" ref-type="bibr"><offsets xml_i="49646" xml_f="49648" txt_i="22955" txt_f="22957">22</offsets></xref></p><p><offsets xml_i="49662" xml_f="49780" txt_i="22958" txt_f="23076">This finding is in line with the similar disease-activity improvements observed in both treatment groups at 21 months.</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="49811" xml_f="49812" txt_i="23076" txt_f="23077">3</offsets></xref><offsets xml_i="49819" xml_f="50185" txt_i="23077" txt_f="23443"> While the superior radiographic results and drug adherence in the infliximab group apparently had little impact on costs and utilities over 2 years, it can currently only be speculated whether such differences could lead to differential physical function or pain in the respective treatment arms and thereby alter the health economic conclusions in the longer term.</offsets></p></sec><sec id="s4b"><title><offsets xml_i="50216" xml_f="50233" txt_i="23445" txt_f="23462">Previous research</offsets></title><p><offsets xml_i="50244" xml_f="50379" txt_i="23463" txt_f="23598">Few randomised, controlled trials of RA have presented cost-effectiveness results based on directly observed costs and quality of life,</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="50411" xml_f="50413" txt_i="23598" txt_f="23600">23</offsets></xref><offsets xml_i="50420" xml_f="50421" txt_i="23600" txt_f="23601">
</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="50453" xml_f="50455" txt_i="23601" txt_f="23603">24</offsets></xref><offsets xml_i="50462" xml_f="50744" txt_i="23603" txt_f="23885"> none addressing methotrexate-refractory early disease. The BeSt trial found initial combination of methotrexate and infliximab in early RA to result in more QALYs and reduced productivity losses, as compared to a strategy commencing with methotrexate, sulfasalazine and prednisone,</offsets><xref rid="R23" ref-type="bibr"><offsets xml_i="50776" xml_f="50778" txt_i="23885" txt_f="23887">23</offsets></xref><offsets xml_i="50785" xml_f="50871" txt_i="23887" txt_f="23973"> though criticism has been raised for the failure to adjust for baseline productivity.</offsets><xref rid="R25" ref-type="bibr"><offsets xml_i="50903" xml_f="50905" txt_i="23973" txt_f="23975">25</offsets></xref><offsets xml_i="50912" xml_f="50979" txt_i="23975" txt_f="24042"> Differences between the treatment groups evened out after 2 years.</offsets><xref rid="R24" ref-type="bibr"><offsets xml_i="51011" xml_f="51013" txt_i="24042" txt_f="24044">24</offsets></xref><offsets xml_i="51020" xml_f="51463" txt_i="24044" txt_f="24487"> None of the BeSt strategies started with triple therapy, frequent treatment adjustments were allowed, and patients had not previously failed methotrexate, making comparisons with our results difficult. The potential of the Swefot trial to detect differential effects on work loss or utility occurring early after initiation of combination therapy may have been decreased by the improvements seen already during the methotrexate run-in period.</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="51494" xml_f="51495" txt_i="24487" txt_f="24488">4</offsets></xref><offsets xml_i="51502" xml_f="51503" txt_i="24488" txt_f="24489">
</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="51534" xml_f="51535" txt_i="24489" txt_f="24490">5</offsets></xref></p><p><offsets xml_i="51549" xml_f="51597" txt_i="24491" txt_f="24539">A review of the modelling literature by Schoels </offsets><italic><offsets xml_i="51605" xml_f="51610" txt_i="24539" txt_f="24544">et al</offsets></italic><xref rid="R7" ref-type="bibr"><offsets xml_i="51650" xml_f="51651" txt_i="24544" txt_f="24545">7</offsets></xref><offsets xml_i="51658" xml_f="51768" txt_i="24545" txt_f="24655"> report that TNF inhibitors appear cost-effective after failure with conventional DMARDs, while van der Velde </offsets><italic><offsets xml_i="51776" xml_f="51781" txt_i="24655" txt_f="24660">et al</offsets></italic><xref rid="R8" ref-type="bibr"><offsets xml_i="51821" xml_f="51822" txt_i="24660" txt_f="24661">8</offsets></xref><offsets xml_i="51829" xml_f="52404" txt_i="24661" txt_f="25236"> conclude that the most cost-effective approach in early RA appears to be to start with a sequence of conventional DMARDs, adding a biologic in case of continued non-response, but doing so before late stages of disease are reached. Either way, the available modelling results are principally based on studies of patients with established RA, and previous exposure to at least two traditional DMARDs, TNF inhibitors added to methotrexate are often compared with continued methotrexate monotherapy, and no available cost-effectiveness analyses use triple therapy as comparator.</offsets><xref rid="R7" ref-type="bibr"><offsets xml_i="52435" xml_f="52436" txt_i="25236" txt_f="25237">7</offsets></xref><offsets xml_i="52443" xml_f="52444" txt_i="25237" txt_f="25238">
</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="52475" xml_f="52476" txt_i="25238" txt_f="25239">8</offsets></xref></p><p><offsets xml_i="52490" xml_f="52653" txt_i="25240" txt_f="25403">Combining data from various sources to estimate cost-effectiveness over extended time horizons, modelling studies inevitably require a large number of assumptions,</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="52685" xml_f="52687" txt_i="25403" txt_f="25405">26</offsets></xref><offsets xml_i="52694" xml_f="53163" txt_i="25405" txt_f="25874"> and comparisons to our trial-based results are hampered by the great methodological differences. Apart from the higher drug costs of the infliximab group, our high incremental cost-effectiveness ratio was largely driven by the absence of a between-group difference in QALYs, while cost reductions were also not observed in healthcare use or productivity—all variables that modelling studies often derive indirectly from other clinical parameters such as the HAQ score.</offsets><xref rid="R8" ref-type="bibr"><offsets xml_i="53194" xml_f="53195" txt_i="25874" txt_f="25875">8</offsets></xref><offsets xml_i="53202" xml_f="53203" txt_i="25875" txt_f="25876">
</offsets><xref rid="R26" ref-type="bibr"><offsets xml_i="53235" xml_f="53237" txt_i="25876" txt_f="25878">26</offsets></xref></p><p><offsets xml_i="53251" xml_f="53549" txt_i="25879" txt_f="26177">The recent TEAR trial compared methotrexate plus etanercept to triple therapy in early RA, reporting similar clinical outcomes and small radiographic differences after 2 years, whether the strategies were used as first-line treatment or following inadequate methotrexate response (as in our study).</offsets><xref rid="R27" ref-type="bibr"><offsets xml_i="53581" xml_f="53583" txt_i="26177" txt_f="26179">27</offsets></xref><offsets xml_i="53590" xml_f="53860" txt_i="26179" txt_f="26449"> Likewise, similar radiographic and clinical outcomes between treatment arms were found after 5 years of follow-up in the NEO-RACo trial, where early RA patients were randomised to receive either initial infliximab or placebo infusions in addition to combination DMARDs.</offsets><xref rid="R28" ref-type="bibr"><offsets xml_i="53892" xml_f="53894" txt_i="26449" txt_f="26451">28</offsets></xref><offsets xml_i="53901" xml_f="54168" txt_i="26451" txt_f="26718"> Furthermore, in patients with established RA and active disease despite methotrexate therapy, triple therapy was recently reported to be non-inferior to methotrexate plus etanercept after 48 weeks regarding reduction of disease activity and radiographic progression.</offsets><xref rid="R29" ref-type="bibr"><offsets xml_i="54200" xml_f="54202" txt_i="26718" txt_f="26720">29</offsets></xref><offsets xml_i="54209" xml_f="54370" txt_i="26720" txt_f="26881"> Although no health economic analyses have been presented based on these trials, it stands to reason that the results would strongly favour conventional therapy.</offsets></p><p><offsets xml_i="54377" xml_f="54746" txt_i="26882" txt_f="27251">While we believe our overall findings to be generalisable, the detailed cost results may not be transferable to non-Swedish settings due to the different healthcare and social insurance systems in different countries. Nonetheless, drug and healthcare costs were comparable to those of the BeSt trial, while our register-assessed productivity loss estimates were higher.</offsets></p></sec><sec id="s4c"><title><offsets xml_i="54777" xml_f="54789" txt_i="27253" txt_f="27265">Implications</offsets></title><p><offsets xml_i="54800" xml_f="55076" txt_i="27266" txt_f="27542">Based on the 2-year Swefot results, in early, methotrexate-refractory RA, an attempt with conventional triple therapy appears reasonable from a clinical and economic viewpoint before starting infliximab treatment. Larger studies may, however, be needed to confirm our finding.</offsets></p></sec><sec id="s4d"><title><offsets xml_i="55107" xml_f="55116" txt_i="27544" txt_f="27553">Strengths</offsets></title><p><offsets xml_i="55127" xml_f="55350" txt_i="27554" txt_f="27777">We addressed a central question of early RA—whether, in the face of insufficient methotrexate response, the addition of a costly anti-TNF agent offers good value for money, as compared to adding further conventional DMARDs.</offsets></p><p><offsets xml_i="55357" xml_f="55857" txt_i="27778" txt_f="28278">Data on healthcare use and work loss were retrieved via linkage to national registers, avoiding non-response and recall bias associated with capturing costs by questionnaires. Combined with quality of life and drug use data, this enabled a cost-effectiveness study based solely on direct observations, something not previously available for the treatments studied, and to the best of our knowledge representing the first cost-effectiveness analysis of a register-enriched randomised controlled trial.</offsets></p><p><offsets xml_i="55864" xml_f="55875" txt_i="28279" txt_f="28290">As seen in </offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="55929" xml_f="55936" txt_i="28290" txt_f="28297">table 2</offsets></xref><offsets xml_i="55943" xml_f="56391" txt_i="28297" txt_f="28745">, following protocol breach, patients in the conventional arm often received biologic therapy, thus decreasing between-group drug cost differences. To reflect reality, we analysed costs and utilities accumulated during the full 21 months follow-up in all patients by the intention-to-treat principle, thereby comparing two treatment strategies, commencing with addition of either infliximab or further conventional DMARDs upon methotrexate failure.</offsets></p></sec><sec id="s4e"><title><offsets xml_i="56422" xml_f="56433" txt_i="28747" txt_f="28758">Limitations</offsets></title><p><offsets xml_i="56444" xml_f="56527" txt_i="28759" txt_f="28842">The open-label design is a limitation of the Swefot trial, as discussed previously.</offsets><xref rid="R2" ref-type="bibr"><offsets xml_i="56558" xml_f="56559" txt_i="28842" txt_f="28843">2</offsets></xref><offsets xml_i="56566" xml_f="56567" txt_i="28843" txt_f="28844">
</offsets><xref rid="R3" ref-type="bibr"><offsets xml_i="56598" xml_f="56599" txt_i="28844" txt_f="28845">3</offsets></xref><offsets xml_i="56606" xml_f="56984" txt_i="28845" txt_f="29223"> Moreover, the relatively short time horizon, the limited study sample totalling 258 randomised individuals, and powering of the trial to detect a between-group difference in clinical response, and not in costs or QALYs, all entail risks of type two error. However, rather than diverging, quality of life and work loss both followed similar trajectories in the two study groups,</offsets><xref rid="R4" ref-type="bibr"><offsets xml_i="57015" xml_f="57016" txt_i="29223" txt_f="29224">4</offsets></xref><offsets xml_i="57023" xml_f="57024" txt_i="29224" txt_f="29225">
</offsets><xref rid="R5" ref-type="bibr"><offsets xml_i="57055" xml_f="57056" txt_i="29225" txt_f="29226">5</offsets></xref><offsets xml_i="57063" xml_f="57132" txt_i="29226" txt_f="29295"> while the higher drug costs in the infliximab arm were considerable.</offsets></p><p><offsets xml_i="57139" xml_f="57502" txt_i="29296" txt_f="29659">We did not include costs of primary care, community care and transportation, informal care, patients' out of pocket expenses, or loss of unpaid work and leisure time. In a Swedish survey from 2002, these parameters (loss of unpaid work not included) accounted for 16% of total societal costs in a cohort of patients with established RA of whom 14% used biologics.</offsets><xref rid="R30" ref-type="bibr"><offsets xml_i="57534" xml_f="57536" txt_i="29659" txt_f="29661">30</offsets></xref><offsets xml_i="57543" xml_f="57708" txt_i="29661" txt_f="29826"> Based on this and on the absence of a between-group difference in QALYs, potential cost differences in these items would be unlikely to change the study conclusion.</offsets></p><p><offsets xml_i="57715" xml_f="58141" txt_i="29827" txt_f="30253">The intravenous infliximab administration may partly explain the higher healthcare use in the infliximab group. Apart from infusion logistics, the frequent visits could potentially also generate more medical interventions in general. Again, however, in the absence of a QALY difference, and with the large drug cost difference, exclusion of such preparation-driven expenses would only have minor impact on the present results.</offsets></p><p><offsets xml_i="58148" xml_f="58547" txt_i="30254" txt_f="30653">Future potential price decreases for infliximab may be anticipated to change the cost-effectiveness outcome. In our analysis, however, even ascribing the same price to both treatment strategies would not produce incremental cost-effectiveness ratios below generally accepted willingness-to-pay levels, due to the lack of a difference in effect and the higher healthcare use in the infliximab group (</offsets><xref ref-type="table" rid="ANNRHEUMDIS2013205060TB2"><offsets xml_i="58601" xml_f="58608" txt_i="30653" txt_f="30660">table 2</offsets></xref><offsets xml_i="58615" xml_f="58617" txt_i="30660" txt_f="30662">).</offsets></p></sec><sec id="s4f"><title><offsets xml_i="58648" xml_f="58659" txt_i="30664" txt_f="30675">Conclusions</offsets></title><p><offsets xml_i="58670" xml_f="59064" txt_i="30676" txt_f="31070">In patients with methotrexate-refractory early RA, a treatment strategy commencing with addition of infliximab, as compared with sulfasalazine and hydroxychloroquine, was associated with similar effects but higher costs over 21 months. Less radiographic progression was, however, observed with the infliximab strategy, calling for future studies to assess cost-effectiveness in the longer term.</offsets></p></sec></sec><sec sec-type="supplementary-material"><title><offsets xml_i="59126" xml_f="59148" txt_i="31073" txt_f="31095">Supplementary Material</offsets></title><supplementary-material content-type="local-data" id="SD1"><caption><title><offsets xml_i="59231" xml_f="59245" txt_i="31096" txt_f="31110">Web supplement</offsets></title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="annrheumdis-2013-205060-s1.pdf" xlink:type="simple" id="d35e1660" position="anchor"></media></supplementary-material></sec></body><back><ack><p>We are indebted to all patients, colleagues and staff who made the Swefot trial possible.</p></ack><fn-group><fn><p><bold>Contributors:</bold> JKE, JAK and MN had full access to all of the data in the study and take responsibility for the accuracy of the data analysis. Trial design: JB, SE, PG, IFP, RFvV. Recruitment of patients: JB, SE, PG, IFP, RFvV. Inclusion and follow-up visits: JB, SE, PG, IFP, RFvV. Quality control of data: JB, JKE, SE, PG, JAK, MN, RFvV. Analysis and interpretation of data: JKE, JAK, MN. Drafting of the manuscript: JKE, JAK, MN. Critical revision of the manuscript for important intellectual content: JB, JKE, SE, PG, JAK, MN, IFP, RFvV. Study supervision: JB, SE, PG, IFP, RFvV.</p></fn><fn><p><bold>Funding:</bold> The study was funded by the Swedish Rheumatism Association, Stockholm County, and Schering-Plough/Merck Sharp and Dohme. The funding sources had no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. Researchers were independent from the funders and sponsors of the study.</p></fn><fn><p><bold>Competing interests:</bold> RFvV has received research support and honoraria from Abbott, GSK/HGS, MSD, Pfizer, Roche and UCB Pharma. MN reported participating in advisory boards for Pfizer (rheumatology) and Abbott (non-rheumatology; unrelated to the current work); participating in research projects fully or partly funded by Schering-Plough, Astra Zeneca, Novo Nordisk, Pfizer, and Roche (unrelated to the current work); and serving as an external consultant (unrelated to rheumatology since 2008) to Pfizer, Sanofi-Aventis, Roche and Abbott. Remaining authors declare no conflict of interest.</p></fn><fn><p><bold>Ethics approval:</bold> The Swefot study was approved by regional ethics committees of all participating units. All participants gave written informed consent before inclusion. The Swefot trial is registered in the WHO database at the Karolinska Hospital, number CT20080004, and clinicaltrials.gov Identifier: NCT00764725.</p></fn><fn><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauer</surname><given-names>MS</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name></person-group>
<article-title>The randomized registry trial—the next disruptive technology in clinical research?</article-title>
<source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>1579</fpage>–<lpage>81</lpage>.<pub-id pub-id-type="pmid"></pub-id></mixed-citation></ref><ref id="R2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name><name><surname>Ernestam</surname><given-names>S</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial</article-title>. <source>Lancet</source>
<year>2009</year>;<volume>374</volume>:<fpage>459</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">19665644</pub-id></mixed-citation></ref><ref id="R3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Vollenhoven</surname><given-names>RF</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><name><surname>Forslind</surname><given-names>K</given-names></name><etal></etal></person-group>
<article-title>Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial</article-title>. <source>Lancet</source>
<year>2012</year>;<volume>379</volume>:<fpage>1712</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">22464340</pub-id></mixed-citation></ref><ref id="R4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karlsson</surname><given-names>JA</given-names></name><name><surname>Neovius</surname><given-names>M</given-names></name><name><surname>Nilsson</surname><given-names>JA</given-names></name><etal></etal></person-group>
<article-title>Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trial</article-title>. <source>Ann Rheum Dis</source>
<year>2013</year>;<volume>72</volume>:<fpage>1927</fpage>–<lpage>33</lpage>.<pub-id pub-id-type="pmid">23196701</pub-id></mixed-citation></ref><ref id="R5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eriksson</surname><given-names>JK</given-names></name><name><surname>Neovius</surname><given-names>M</given-names></name><name><surname>Bratt</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Biological vs. conventional combination treatment and work loss in early rheumatoid arthritis: a randomized trial</article-title>. <source>JAMA Intern Med</source>
<year>2013</year>;<volume>173</volume>:<fpage>1407</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">23817631</pub-id></mixed-citation></ref><ref id="R6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neovius</surname><given-names>M</given-names></name><name><surname>Sundstrom</surname><given-names>A</given-names></name><name><surname>Simard</surname><given-names>J</given-names></name><etal></etal></person-group>
<article-title>Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009</article-title>. <source>Scand J Rheumatol</source>
<year>2011</year>;<volume>40</volume>:<fpage>8</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">20955087</pub-id></mixed-citation></ref><ref id="R7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schoels</surname><given-names>M</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Scott</surname><given-names>DL</given-names></name><etal></etal></person-group>
<article-title>Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis</article-title>. <source>Ann Rheum Dis</source>
<year>2010</year>;<volume>69</volume>:<fpage>995</fpage>–<lpage>1003</lpage>.<pub-id pub-id-type="pmid">20447950</pub-id></mixed-citation></ref><ref id="R8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Velde</surname><given-names>G</given-names></name><name><surname>Pham</surname><given-names>B</given-names></name><name><surname>Machado</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Cost-effectiveness of biologic response modifiers compared to disease-modifying antirheumatic drugs for rheumatoid arthritis: a systematic review</article-title>. <source>Arthritis Care Res (Hoboken)</source>
<year>2011</year>;<volume>63</volume>:<fpage>65</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">20740606</pub-id></mixed-citation></ref><ref id="R9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arnett</surname><given-names>FC</given-names></name><name><surname>Edworthy</surname><given-names>SM</given-names></name><name><surname>Bloch</surname><given-names>DA</given-names></name><etal></etal></person-group>
<article-title>The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>
<year>1988</year>;<volume>31</volume>:<fpage>315</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">3358796</pub-id></mixed-citation></ref><ref id="R10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prevoo</surname><given-names>ML</given-names></name><name><surname>van't Hof</surname><given-names>MA</given-names></name><name><surname>Kuper</surname><given-names>HH</given-names></name><etal></etal></person-group>
<article-title>Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>
<year>1995</year>;<volume>38</volume>:<fpage>44</fpage>–<lpage>8</lpage>.<pub-id pub-id-type="pmid">7818570</pub-id></mixed-citation></ref><ref id="R11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Gestel</surname><given-names>AM</given-names></name><name><surname>Prevoo</surname><given-names>ML</given-names></name><name><surname>van't Hof</surname><given-names>MA</given-names></name><etal></etal></person-group>
<article-title>Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria</article-title>. <source>Arthritis Rheum</source>
<year>1996</year>;<volume>39</volume>:<fpage>34</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">8546736</pub-id></mixed-citation></ref><ref id="R12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ludvigsson</surname><given-names>JF</given-names></name><name><surname>Andersson</surname><given-names>E</given-names></name><name><surname>Ekbom</surname><given-names>A</given-names></name><etal></etal></person-group>
<article-title>External review and validation of the Swedish national inpatient register</article-title>. <source>BMC Public Health</source>
<year>2011</year>;<volume>11</volume>:<fpage>450</fpage>.<pub-id pub-id-type="pmid">21658213</pub-id></mixed-citation></ref><ref id="R13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Askling</surname><given-names>J</given-names></name><name><surname>Fored</surname><given-names>CM</given-names></name><name><surname>Geborek</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>Swedish registers to examine drug safety and clinical issues in RA</article-title>. <source>Ann Rheum Dis</source>
<year>2006</year>;<volume>65</volume>:<fpage>707</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">16414975</pub-id></mixed-citation></ref><ref id="R14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koopmanschap</surname><given-names>MA</given-names></name><name><surname>Rutten</surname><given-names>FF</given-names></name><name><surname>van Ineveld</surname><given-names>BM</given-names></name><etal></etal></person-group>
<article-title>The friction cost method for measuring indirect costs of disease</article-title>. <source>J Health Econ</source>
<year>1995</year>;<volume>14</volume>:<fpage>171</fpage>–<lpage>89</lpage>.<pub-id pub-id-type="pmid">10154656</pub-id></mixed-citation></ref><ref id="R15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>R</given-names></name></person-group>
<article-title>EuroQol: the current state of play</article-title>. <source>Health Policy</source>
<year>1996</year>;<volume>37</volume>:<fpage>53</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">10158943</pub-id></mixed-citation></ref><ref id="R16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolan</surname><given-names>P</given-names></name></person-group>
<article-title>Modeling valuations for EuroQol health states</article-title>. <source>Med Care</source>
<year>1997</year>;<volume>35</volume>:<fpage>1095</fpage>–<lpage>108</lpage>.<pub-id pub-id-type="pmid">9366889</pub-id></mixed-citation></ref><ref id="R17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>JW</given-names></name><name><surname>Johnson</surname><given-names>JA</given-names></name><name><surname>Coons</surname><given-names>SJ</given-names></name></person-group>
<article-title>US valuation of the EQ-5D health states: development and testing of the D1 valuation model</article-title>. <source>Med Care</source>
<year>2005</year>;<volume>43</volume>:<fpage>203</fpage>–<lpage>20</lpage>.<pub-id pub-id-type="pmid">15725977</pub-id></mixed-citation></ref><ref id="R18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Willan</surname><given-names>AR</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Hoch</surname><given-names>JS</given-names></name></person-group>
<article-title>Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data</article-title>. <source>Health Econ</source>
<year>2004</year>;<volume>13</volume>:<fpage>461</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">15127426</pub-id></mixed-citation></ref><ref id="R19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>SG</given-names></name><name><surname>Barber</surname><given-names>JA</given-names></name></person-group>
<article-title>How should cost data in pragmatic randomised trials be analysed?</article-title>
<source>BMJ</source>
<year>2000</year>;<volume>320</volume>:<fpage>1197</fpage>–<lpage>200</lpage>.<pub-id pub-id-type="pmid">10784550</pub-id></mixed-citation></ref><ref id="R20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Hout</surname><given-names>BA</given-names></name><name><surname>Al</surname><given-names>MJ</given-names></name><name><surname>Gordon</surname><given-names>GS</given-names></name><etal></etal></person-group>
<article-title>Costs, effects and C/E-ratios alongside a clinical trial</article-title>. <source>Health Econ</source>
<year>1994</year>;<volume>3</volume>:<fpage>309</fpage>–<lpage>19</lpage>.<pub-id pub-id-type="pmid">7827647</pub-id></mixed-citation></ref><ref id="R21"><label>21</label><mixed-citation publication-type="book"><collab>NICE</collab>. <source><italic>Methods for the development of NICE public health guidance</italic></source>. <edition>3rd edn</edition>
<year>2012</year>
<comment>[cited 2013 April 3]. <ext-link ext-link-type="uri" xlink:href="http://publications.nice.org.uk/methods-for-the-development-of-nice-public-health-guidance-third-edition-pmg4">http://publications.nice.org.uk/methods-for-the-development-of-nice-public-health-guidance-third-edition-pmg4</ext-link></comment></mixed-citation></ref><ref id="R22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shiroiwa</surname><given-names>T</given-names></name><name><surname>Sung</surname><given-names>YK</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><etal></etal></person-group>
<article-title>International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness?</article-title>
<source>Health Econ</source>
<year>2010</year>;<volume>19</volume>:<fpage>422</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">19382128</pub-id></mixed-citation></ref><ref id="R23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hout</surname><given-names>WB</given-names></name><name><surname>Goekoop-Ruiterman</surname><given-names>YP</given-names></name><name><surname>Allaart</surname><given-names>CF</given-names></name><etal></etal></person-group>
<article-title>Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis</article-title>. <source>Arthritis Rheum</source>
<year>2009</year>;<volume>61</volume>:<fpage>291</fpage>–<lpage>9</lpage>.<pub-id pub-id-type="pmid">19248130</pub-id></mixed-citation></ref><ref id="R24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Hout</surname><given-names>W</given-names></name><name><surname>Klarenbeek</surname><given-names>N</given-names></name><name><surname>Dirven</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Long-term cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis—5 year follow-up data from the BeSt study</article-title>. <source>Ann Rheum Dis</source>
<year>2012</year>;<volume>71</volume><issue>(Suppl3)</issue>:<fpage>363</fpage>.<pub-id pub-id-type="pmid">21989539</pub-id></mixed-citation></ref><ref id="R25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boers</surname><given-names>M</given-names></name></person-group>
<article-title>The cost-utility analysis of the BeSt trial: is a camel in fact a horse with abnormalities in the distribution of dorsal fat? Comment on the article by van den Hout <italic>et al</italic></article-title><italic>.</italic>
<source>Arthritis Rheum</source>
<year>2009</year>;<volume>61</volume>:<fpage>1616</fpage>–<lpage>17</lpage>; <comment>author reply 1617–1618</comment>.<pub-id pub-id-type="pmid">19877096</pub-id></mixed-citation></ref><ref id="R26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YF</given-names></name><name><surname>Jobanputra</surname><given-names>P</given-names></name><name><surname>Barton</surname><given-names>P</given-names></name><etal></etal></person-group>
<article-title>A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness</article-title>. <source>Health Technol Assess</source>
<year>2006</year>;<volume>10</volume>:<fpage>iii</fpage>–<lpage>iv</lpage>, <comment>xi-xiii, 1–229</comment>.<pub-id pub-id-type="pmid">17049139</pub-id></mixed-citation></ref><ref id="R27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moreland</surname><given-names>LW</given-names></name><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Paulus</surname><given-names>HE</given-names></name><etal></etal></person-group>
<article-title>A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial</article-title>. <source>Arthritis Rheum</source>
<year>2012</year>;<volume>64</volume>:<fpage>2824</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">22508468</pub-id></mixed-citation></ref><ref id="R28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rantalaiho</surname><given-names>V</given-names></name><name><surname>Kautiainen</surname><given-names>H</given-names></name><name><surname>Korpela</surname><given-names>M</given-names></name><etal></etal></person-group>
<article-title>Targeted treatment with a combination of traditional DMARDs produces excellent clinical and radiographic long-term outcomes in early rheumatoid arthritis regardless of initial infliximab. The 5-year follow-up results of a randomised clinical trial, the NEO-RACo trial</article-title>. <source>Ann Rheum Dis</source>
<comment>2014;73:1954–61.</comment></mixed-citation></ref><ref id="R29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Dell</surname><given-names>JR</given-names></name><name><surname>Mikuls</surname><given-names>TR</given-names></name><name><surname>Taylor</surname><given-names>TH</given-names></name><etal></etal></person-group>
<article-title>Therapies for active rheumatoid arthritis after methotrexate failure</article-title>. <source>N Engl J Med</source>
<year>2013</year>;<volume>369</volume>:<fpage>307</fpage>–<lpage>18</lpage>.<pub-id pub-id-type="pmid">23755969</pub-id></mixed-citation></ref><ref id="R30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobsson</surname><given-names>LT</given-names></name><name><surname>Lindroth</surname><given-names>Y</given-names></name><name><surname>Marsal</surname><given-names>L</given-names></name><etal></etal></person-group>
<article-title>Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden</article-title>. <source>Scand J Rheumatol</source>
<year>2007</year>;<volume>36</volume>:<fpage>179</fpage>–<lpage>83</lpage>.<pub-id pub-id-type="pmid">17657670</pub-id></mixed-citation></ref></ref-list></back></article>